Literature DB >> 28550955

Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort.

Malte W Vetterlein1, Christian P Meyer1, Sami-Ramzi Leyh-Bannurah1, Roman Mayr2, Michael Gierth2, Hans-Martin Fritsche2, Maximilian Burger2, Bastian Keck3, Bernd Wullich3, Thomas Martini4, Christian Bolenz4, Armin Pycha5, Julian Hanske6, Florian Roghmann6, Joachim Noldus6, Patrick J Bastian7, Christian Gilfrich8, Matthias May8, Michael Rink1, Felix K-H Chun1, Roland Dahlem1, Margit Fisch1, Atiqullah Aziz9.   

Abstract

BACKGROUND: Case volume has been suggested to affect surgical outcomes in different arrays of procedures. We aimed to delineate the relationship between case volume and surgical outcomes and quality of care criteria of radical cystectomy (RC) in a prospectively collected multicenter cohort. PATIENTS AND METHODS: This was a retrospective analysis of a prospectively collected European cohort of patients with bladder cancer treated with RC in 2011. We relied on 479 and 459 eligible patients with available information on hospital case volume and surgeon case volume, respectively. Hospital case volume was divided into tertiles, and surgeon volume was dichotomized according to the median annual number of surgeries performed. Binomial generalized estimating equations controlling for potential known confounders and inter-hospital clustering assessed the independent association of case volume with short-term complications and mortality, as well as the fulfillment of quality of care criteria.
RESULTS: The high-volume threshold for hospitals was 45 RCs and, for high-volume surgeons, was > 15 cases annually. In adjusted analyses, high hospital volume remained an independent predictor of fewer 30-day (odds ratio, 0.34; P = .002) and 60- to 90-day (odds ratio, 0.41; P = .03) major complications but not of fulfilling quality of care criteria or mortality. No difference between surgeon volume groups was noted for complications, quality of care criteria, or mortality after adjustments.
CONCLUSION: The coordination of care at high-volume hospitals might confer a similar important factor in postoperative outcomes as surgeon case volume in RC. This points to organizational elements in high-volume hospitals that enable them to react more appropriately to adverse events after surgery.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  High volume; Postoperative complications; Quality of health care; Urinary bladder neoplasms; Volume-outcome relationship

Mesh:

Year:  2017        PMID: 28550955     DOI: 10.1016/j.clgc.2017.04.021

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  4 in total

1.  Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy.

Authors:  Benedikt Hoeh; Rocco Simone Flammia; Lukas Hohenhorst; Gabriele Sorce; Francesco Chierigo; Andrea Panunzio; Zhe Tian; Fred Saad; Michele Gallucci; Alberto Briganti; Carlo Terrone; Shahrokh F Shariat; Markus Graefen; Derya Tilki; Alessandro Antonelli; Luis A Kluth; Philipp Mandel; Felix K H Chun; Pierre I Karakiewicz
Journal:  Cancers (Basel)       Date:  2022-02-26       Impact factor: 6.639

2.  Enhanced recovery after surgery (ERAS) protocols in patients undergoing radical cystectomy with ileal urinary diversions: A randomized controlled trial.

Authors:  Olaru Vlad; Baston Catalin; Harza Mihai; Preda Adrian; Olaru Manuela; Ismail Gener; Sinescu Ioanel
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

3.  Determinants of treatment in patients with stage IV renal cell carcinoma.

Authors:  Christopher S Hollenbeak; Eric W Schaefer; Justin Doan; Jay D Raman
Journal:  BMC Urol       Date:  2019-11-29       Impact factor: 2.264

4.  Bladder Cancer Recovery Pathways: A Systematic Review.

Authors:  Ian Maloney; Daniel C Parker; Michael S Cookson; Sanjay Patel
Journal:  Bladder Cancer       Date:  2017-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.